Improving the life of our patients with next-generation technologies and individual therapies About UsContact Us Improving the life of our patients with next-generation technologies and individual therapies About UsContact Us APEIRON Biologic's work on a drug candidate against COVID-19
Read more
APEIRON Biologic's work on a drug candidate against COVID-19
Read more

APEIRON Biologics at a glance

  • Focused on novel cancer immunotherapies and respiratory treatments
  • First Austrian biotech company to develop a cancer immunotherapy product through to market
    Approval in 2017 of APN311 for treatment of pediatric neuroblastoma in EU and other countries,
    US/Japan BLA filing in preparation
  • Respiratory drug candidate APN01 in clinical development
  • Oncology pipeline in clinical stages
  • Lead by highly experienced and motivated team with global background

NEWS

Reactivated immune cells of cancer patients (APN401) for the treatment of solid tumors
In light of the 21st annual #WorldCancerDay we would like to draw your attention to our work in fighting cancer. We at APEIRON Biologics AG want to make a contribution to people’s #wellbeing by developing the immune therapy APN401. APN401´s proprietary process brings in a paradigm change in cancer treatment to fight hematological and solid...
February 4, 2021
APEIRON Biologics: Patient recruitment completed in Phase II COVID-19 Clinical Trial of APN01
Results of the double-blind, placebo-controlled trial expected in Q1 2021 Preparations for rolling Marketing Authorization Application in Europe commenced Trial results to confirm unique triple mode of action to prevent infection, organ injury and inflammation Press release (EN) | Presseaussendung (DE)
December 4, 2020
APEIRON Biologics AG and Domainex Ltd announce the expansion of their partnership to progress targeted cancer immune therapy drug discovery
Integrated lead optimisation to advance APEIRON’s Cbl-b inhibitor development programme APN431 Inhibitors discovered at Domainex via virtual and fragment screening Press release (EN) | Presseaussendung (DE)
November 9, 2020